Lapland Central Hospital, Rovaniemi, Finland.
J Crohns Colitis. 2012 Jul;6(6):724-7. doi: 10.1016/j.crohns.2012.02.004. Epub 2012 Mar 2.
In recent years, the use of antibodies against tumor necrosis factor α (TNFα) has expanded in rheumatology, gastroenterology, and dermatology. In addition to the more common side effects such as infections and hypersensitivity reactions, elevations of liver enzymes have been reported during anti-TNFα therapy, although severe liver failure has been extremely uncommon. This report describes a patient with severe liver failure after induction therapy with the TNFα antibody infliximab (Remicade®). A 46-year old female patient received two infusions of infliximab at a dose of 400 mg on weeks 0 and 8 for steroid-dependent ulcerative colitis. Eight weeks after the second infusion, she suffered acute liver failure with necrosis, requiring liver transplantation.
近年来，肿瘤坏死因子-α（TNFα）抗体在风湿病学、胃肠病学和皮肤病学中的应用不断扩大。除了更常见的副作用，如感染和过敏反应，在抗 TNFα 治疗期间也有报道称肝酶升高，尽管严重的肝衰竭极为罕见。本报告描述了一例 TNFα 抗体英夫利昔单抗（Remicade®）诱导治疗后发生严重肝衰竭的患者。一名 46 岁女性患者因类固醇依赖型溃疡性结肠炎接受两次英夫利昔单抗输注，剂量为 400mg，分别在第 0 周和第 8 周。第二次输注后 8 周，她发生坏死性急性肝衰竭，需要进行肝移植。
